Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Blood assessment to measure the kinetics au circulating tumor DNA

Measure of the circulating tumor DNA

Fabrice Jardin, MD,PhD

Doriane Richard, PhD

Fabrice Jardin

The purpose of this study is to determine the kinetics of circulating tumor DNA (ctDNA) in the hours following initial administration of immuno-chemotherapy to patients with diffuse large B cell lymphoma (DLBCL). Modelizing the short-term kinetics of ctDNA would help to determine the optimal time-point for ctDNA follow-up. The investigators hypothesize that the greater ctDNA release at this time-point compared to baseline might lead lead to the detection of novel variants compared to baseline.

ctDNA in diffuse large B cell lymphoma (DLBCL) has become an essential dynamic biomarker. Due to its short half-life, ctDNA is a real-time reflection of tumoral evolution and is a non-invasive biomarker that can be used for patient evaluation and follow-up. The quantity of ctDNA before treatment is correlated with tumoral mass, international prognostic index (IPI) and prognosis. The principal mechanism of ctDNA release is tumor cell apoptosis and it is well established that tumor cell apoptosis is observed in the hours following immuno-chemotherapy. However, the kinetics of ctDNA concentration in the hours following immuno-chemotherapy administration is unknown.

Modelizing the kinetics of ctDNA during this early timeframe could help to better predict chemo-sensitivity and better reflect genetic heterogeneity of the tumor, through release of a larger quantity of ctDNA compared to baseline.

Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy

Prospective Study of Circulating Tumor DNA Kinetics Post R-CHOP Type Treatment of Diffuse Large B Cell Lymphoma

Blood assessment to measure circulating tumor concentration

comparison between circulating tumoral concentration and metabolic volume measured on TEP

Centre Henri Becquerel

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy	NCT06141772	Diffuse Large B...	Measure of the ...	18 Years -	Centre Henri Becquerel
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy	NCT06141772	Diffuse Large B...	Measure of the ...	18 Years -	Centre Henri Becquerel
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy	NCT06141772	Diffuse Large B...	Measure of the ...	18 Years -	Centre Henri Becquerel

Spots Global Cancer Trial Database for diffuse large b celle lymphoma